PT  - JOURNAL ARTICLE
AU  - LIDIA MAZUR
AU  - MAŁGORZATA OPYDO-CHANEK
AU  - KATARZYNA ŚLADOWSKA
AU  - BARBARA JANOTA
AU  - URSZULA KŁAPUT
AU  - MAŁGORZATA ŁUKAWSKA
AU  - IRENA OSZCZAPOWICZ
TI  - <em>In Vitro</em> Antileukemic Activity of Formamidine Epidoxorubicin Analogs
DP  - 2017 Nov 01
TA  - Anticancer Research
PG  - 6363--6372
VI  - 37
IP  - 11
4099  - http://ar.iiarjournals.org/content/37/11/6363.short
4100  - http://ar.iiarjournals.org/content/37/11/6363.full
SO  - Anticancer Res2017 Nov 01; 37
AB  - Background/Aim: Epidoxorubicin is an anthracycline agent. The present study was undertaken to compare the antileukemic potential of epidoxorubicin and its two formamidine analogs containing either a morpholine moiety (EPIFmor) or a hexamethyleneimine moiety (EPIFhex) in the amidine group. Materials and Methods: The experiments were performed in vitro on MOLT-4 cells using spectrophotometry, Coulter electrical impedance, flow cytometry, and light microscopy methods. Results: The leukemia cell responses to the action of the anthracyclines were manifested in their different viability, count and volume, degree of apoptosis and necrosis, activity of caspases -8, -9, and -3/7, mitochondrial membrane potential, and in the cell-cycle distribution. In general, epidoxorubicin appeared to be the most active, and EPIFmor was more active than EPIFhex against MOLT-4 cells. Conclusion: The structural modifications of epidoxorubicin in the amidine group were responsible for the varied action of its formamidine analogs on human acute lymphoblastic leukemia cells.